Clinical Trials in Heraklion, Irakleio
7 recruiting
Showing 1–7 of 7 trials
Recruiting
Phase 3
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled149 locationsNCT07060807
Recruiting
Phase 3
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled250 locationsNCT06841354
Recruiting
Phase 3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC780 enrolled257 locationsNCT06312137
Recruiting
Phase 3
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Carcinoma, Non-Small Cell Lung
Merck Sharp & Dohme LLC680 enrolled225 locationsNCT06623422
Recruiting
Phase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Alzheimer Disease
Karuna Therapeutics406 enrolled278 locationsNCT06585787
Recruiting
Phase 2
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
Lung Neoplasm Malignant
Merck Sharp & Dohme LLC60 enrolled31 locationsNCT06788912
Recruiting
Phase 3
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Uveal Melanoma
IDEAYA Biosciences520 enrolled87 locationsNCT07015190